- Carcinoma is the most common cancer, starting in epithelial tissue (skin and organs); it can be in situ, invasive or metastatic.
- Common types: basal cell and squamous cell (skin), clear cell (kidney, ~75% 5-year survival), and ductal (DCIS 99% at stage 0).
- Treatment varies by type and spread: surgery, radiotherapy and chemotherapy.
- Lentinan, the most studied mushroom anticancer compound, is studied for strengthening the immune system.
What is carcinoma?
Carcinoma is the most common type of cancer. It begins in the epithelial tissue of the skin, but can also start in the tissue of other organs, such as the liver or pancreas. Carcinoma can remain at its site of origin or spread to other parts of the body.
- Carcinoma in situ: an early-stage cancer confined to the tissue layer where it began. This cancer has not spread to other organs.
- Invasive carcinoma: cancer that has spread into surrounding tissue.
- Metastatic carcinoma: cancer that has spread to other tissues and organs.
The most common carcinomas
Carcinomas can arise in many parts of the body. The most common types are:
- Basal cell carcinoma: the most common skin cancer. The cancer cells develop in the basal layer of the skin. Basal cells usually grow more slowly, so metastasis and spread are less likely.
- Squamous cell carcinoma: the second most common skin cancer. The cancer cells develop in the squamous cells of the outer skin layer. It usually grows slowly, so metastasis is also less common.
- Clear cell carcinoma: the most common type of kidney cancer, arising in the cells of the kidney tubules. The overall five-year survival for kidney carcinoma is about 75%;6 after surgical removal (nephrectomy) the prognosis improves.
- Ductal carcinoma in situ (DCIS): the most common type of breast cancer, where cancer cells are confined to the milk-duct walls and have not spread to surrounding breast tissue. DCIS (stage 0) has a five-year survival of 99%.8
- Invasive ductal carcinoma: cells have mutated in the milk ducts and penetrated surrounding tissue, from where the cancer can spread to other parts of the body.
Carcinoma treatment
Treatment varies depending on the type, location, size and extent of spread, but may include: Surgery — depending on the cancer type, the carcinoma may be removed surgically along with surrounding tissue; minimally invasive techniques reduce recovery time and infection risk. Radiotherapy — may be used together with surgery and/or chemotherapy. Chemotherapy — one of the most common treatments, using anticancer drugs directed at rapidly dividing cells throughout the body or in a specific area.
What can I do in the fight against carcinoma?
Alcohol is toxic to cells, so its use can accelerate damage with avoidable consequences — giving it up is advisable. Mushrooms have been used as medicine for thousands of years for their unmatched pharmacological diversity. Lentinan, from the Lentinus edodes medicinal mushroom, is the most thoroughly studied and documented anticancer compound. Cancer knows how to send cloaking signals, so the immune system finds it hard to detect — lentinan strengthens the immune system. The amount depends on the stage; the more these mushroom extracts are used, the better the results, with a minimum recommended course of 3 months.
Cancer cells evade immune detection. Lentinan, the most studied mushroom anticancer compound, is studied for strengthening the immune system.
Lentinan AXT by Zenius Labs™ →Carcinoma is the most common type of cancer, beginning in epithelial tissue — usually the skin, but also organs such as the liver or pancreas. It can be in situ (confined), invasive (spread into surrounding tissue), or metastatic (spread to other organs).
The most common are basal cell carcinoma (most common skin cancer, slow-growing), squamous cell carcinoma (second most common skin cancer), clear cell carcinoma (most common kidney cancer, ~75% five-year survival), and ductal carcinoma — DCIS (stage 0, 99% five-year survival) and invasive ductal carcinoma.
Treatment varies by type, location, size and spread, but may include surgery (often minimally invasive), radiotherapy, and chemotherapy directed at rapidly dividing cells.
Yes. Cancer cells evade immune detection with cloaking signals. Lentinan, the most studied mushroom-derived anticancer compound, is studied for strengthening the immune system. A concentrated formula such as Lentinan AXT by Zenius Labs™ is preferable; the minimum recommended course is 3 months.
- A 5-year follow-up study of 633 cutaneous SCC excisions: rates of local recurrence and lymph node metastasis. PubMed
- A 5-year follow-up study of cutaneous SCC excisions: local recurrence and lymph node metastasis. JPRAS
- Kidney Cancer Survival Rates. cancer.org
- Surveillance strategies for renal cell carcinoma patients following nephrectomy. PubMed
- Breast Cancer Survival Rates. cancer.org
- Long-term outcomes of ductal carcinoma in situ: a systematic review, meta-analysis and meta-regression analysis. PubMed
- Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment. Nature / Modern Pathology
- Breast Cancer Statistics. cancer.net
- Second Cancers in Adults — Treatment Risks. cancer.org
- Radiation Therapy Effects on Different Parts of the Body. cancer.org
- Radiation Therapy Side Effects. cancer.gov
- How does alcohol cause cancer? Cancer Research UK
- Effects of lentinan alone and in combination with fluoropyrimidine anticancer agent on growth of human oral squamous cell carcinoma. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
- Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
- Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine. 2014. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
- Zhou G et al. Lentinan progress in inflammatory diseases and tumor diseases. European journal of medical research. 2024. PubMed
- Deng S et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR. 2018. PubMed
- You J et al. Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis. Oncology reports. 2023. PubMed
- Amino M et al. [Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy. 1983. PubMed
- Zhen C et al. Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: A review. Colloids and surfaces. B, Biointerfaces. 2026. PubMed
- Chihara G Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Developments in biological standardization. 1992. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
- Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology. 2013. PubMed
- Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research. 2012. PubMed
- Chang Y et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discovery medicine. 2017. PubMed
- Standish LJ et al. Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology. 2008. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed
- Copat C et al. Astaxanthin in cancer therapy and prevention (Review). Biomedical reports. 2025. PubMed
- Li J et al. Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro. Marine drugs. 2015. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
- Saini RK et al. Dietary carotenoids in cancer chemoprevention and chemotherapy: A review of emerging evidence. Pharmacological research. 2020. PubMed
- Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
- Dan A et al. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus. 2023. PubMed